AZ scores a top spot in best-employer ranking; Valeant says it's still unclear when CEO Pearson might return;

@FiercePharma: U.S.-based Certara creates drug developing consultancy in China. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: J&J will boost workforce at South Africa consumer meds plant after $18M upgrade. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: head Slaoui says the company's vax and businesses need each other--aka, no break-up, please. Article | Follow @CarlyHFierce

> AstraZeneca ($AZN) ranked as the U.K.'s second-best employer in a study by Bloomberg, behind Jaguar Land Rover and way ahead of rival GlaxoSmithKline ($GSK), which came in 50th. Report

> It's still unclear when Valeant ($VRX) CEO J. Michael Pearson will return to the company, interim chief Howard Schiller told investors Wednesday. Report

> Justices on Delaware's Supreme Court are weighing an appeal by AbbVie ($ABBV) investors who want access to documents related to the company's failed $55 billion bid for Shire ($SHPG). Report

> AstraZeneca aims to roll out more of its branded rugs in India, with cancer, lung disease and diabetes the first areas of focus. Report

Medical Device News

@FierceMedDev: Medical device sales reps scouting out new jobs in 2016: Report. More | Follow @FierceMedDev

@EmilyWFierce: Olympus, FDA implicated in Senate probe of duodenoscope devices. Report | Follow @EmilyWFierce

> Hospira pump business nears chopping block as Pfizer mulls potential sale: Bloomberg. More

> FDA makes increasing use of 'real-world' device data a strategic priority. Report

> JPM: Boston Sci updates on Watchman reimbursement, Synergy launch. Article

Biotech News

@FierceBiotech: Biden maps out a 'moonshot' approach to cancer with plans to 'break down silos' in R&D. More | Follow @FierceBiotech

@JohnCFierce: FDA slaps down BioMarin's Duchenne's drug as rival nears a moment of truth. News | Follow @JohnCFierce

@DamianFierce: "I made a point to talk to female guests," he said. More from Bloomberg | Follow @DamianFierce

> Celgene chief Bob Hugin ponders a new era for neurodegeneration R&D. Report

> Pfizer looks to cut the line in CAR-T with off-the-shelf approach. Article

> Biotech has a problem with women? Or is it the other way around? More

Pharma Manufacturing News

> U.K.'s Oxford BioMedica gets MHRA nod for new manufacturing facility. Item

> GSK turns to K+N for supplier logistics. News

> FDA finds issues with Walgreens' infusion compounding services. Report

> EMA says Spain has taken action against drugmaker for shortcomings. Story

> Bayer opens large China plant for traditional Chinese and Western OTC meds. Article

CRO News

> Evotec hits an R&D milestone with J&J in an ambitious Alzheimer's collaboration. News

> Eurofins buys Dutch drug-testing firm to pad its services. More

> AMRI signs a trio of deals in R&D, manufacturing and marketing. Report

> Catalent inks a $619M deal to help Roche develop targeted therapies. Article

Pharma Asia News

> China-focused CASI Pharmaceuticals gets Marqbio review by CFDA. Item

> China continues to find problems in drug production. Article

> In Japan, fast approvals, more R&D cash and price cuts ahead. Report

> Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet. More

> Cipla says top 50 drugs in development could bring in $30B. Story

And Finally... Statins may help patients recover after bypass surgery, a study review found. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.